Active, not recruitingPhase 3NCT04770753
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
Studying Alpha-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agios Pharmaceuticals, Inc.
- Principal Investigator
- Medical AffairsAgios Pharmaceuticals, Inc.
- Intervention
- Placebo Matching Mitapivat(drug)
- Enrollment
- 194 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- San Diego Hospital, UC San Diego Health, La Jolla, California, United States
- Stanford Medicine, Palo Alto, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Weill Cornell Medical Center, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Penn Medicine - University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
- Universidade de Caxias do Sul, Caxias do Sul, Brazil
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, Brazil
- HEMORIO Instituto Nacional de Hematologia, Rio de Janeiro, Brazil
- Praxis Pesquisa Medica, Santo André, Brazil
- GSH Banco de Sangue de São Paulo, São Paulo, Brazil
- Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas da Faculdade de Medicina da Universidad de São Paulo, São Paulo, Brazil
- MHAT "Dr. Nikola Vasiliev" AD, Kyustendil, Bulgaria
- SHATHD Sofia, Sofia, Bulgaria
- Toronto General Hospital, University Health Network, Toronto, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04770753 on ClinicalTrials.govOther trials for Alpha-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06591936Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .Sohag University
- RECRUITINGNANCT06539169FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesxCures
- RECRUITINGEARLY PHASE1NCT06107400Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring DiseaseThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
- RECRUITINGPHASE2NCT05664737A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaBristol-Myers Squibb
- ACTIVE NOT RECRUITINGPHASE3NCT04770779A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Agios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGNANCT02692872Screening for Alpha Thalassemia in Healthy VolunteersNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT04872179International Registry of Patients With Alpha ThalassemiaUniversity of California, San Francisco